

May 2016

**STOCK INFORMATION** (as of May 9, 2016)

**Ticker:** CEMI  
**Exchange:** Nasdaq  
**Share Price:** \$7.35/share  
**Market Cap:** \$70.93 Million

**CORPORATE HIGHLIGHTS**

- Global Provider of High Quality POC Infectious Disease Assays
  - Sales in 40+ countries, including U.S.
- Consistent Revenue Growth (5 Year 8% CAGR)
- Patented DPP® Technology
  - DPP® HIV 1/2 Assay for Blood/Oral Fluid - FDA Approved & CLIA-Waived
  - Multiple products sold into Latin America and U.S.
- Future Pipeline of DPP® POC Assays (internal development)
  - DPP® HIV-Syphilis Combination Assay (U.S.)
  - DPP® Malaria Assay
  - DPP® Chikungunya Assay
- Ongoing Collaborations/Development Projects:
  - DPP® Malaria Assay (Oral Fluid/Saliva)
  - DPP® Zika Assay
  - DPP® Dengue Assay
  - DPP® Zika/Dengue/Chikungunya Assay
  - DPP® Fever Panel Assay
  - DPP® Malaria/Ebola Assay
  - DPP® Ebola Assay
  - DPP® Flu Immunostatus
  - DPP® Traumatic Brain Injury
  - DPP® Cancer (specific form)
  - DPP® Micro Reader

**COMPANY SNAPSHOT**

**Chembio Diagnostics, Inc.** (NASDAQ: CEMI) develops, manufactures, licenses and markets rapid diagnostic assays in the growing \$8.0 billion point-of-care (POC) testing market. In addition to its branded and proprietary HIV assays, which it sells in the U.S. and internationally, the Company has several ongoing collaborations for the development of diagnostic assays for Malaria, Dengue, Zika, Chikungunya, Ebola, Lassa, Marburg, flu immunostatus, brain injury and a specific form of cancer.


**Dual Path Platform (DPP®)** is Chembio's patented POC technology, which offers significant advantages over lateral-flow technologies including enhanced sensitivity and the ability to conduct multiple tests from a single sample (multiplexing). DPP® continues to provide Chembio with a growing pipeline of business opportunities for the development and manufacture of new products.

**CHEMBIO'S LEAD PRODUCTS**

**DPP® HIV-Syphilis Assay**

*\*available in selected markets*

- Rapid, multiplex detection of HIV 1, HIV 2, and syphilis using a single sample




**DPP® HIV 1/2 Assay**

- Rapid detection of HIV 1 and HIV 2 antibodies in oral fluid and all blood matrices



**HIV 1/2 STAT-PAK® Assay**

- Single-use, rapid, visual detection of HIV 1 and HIV 2 antibodies



**SURE CHECK® HIV 1/2 Assay**


- Self-contained, single-use collection & testing device



# CHEMBIO'S DPP® DUAL PATH PLATFORM

- Patented technology
- Allows improved sensitivity and specificity compared to lateral flow technology
- Enables multiple test results via a single blood sample (e.g., HIV-Syphilis Combo Assay)
- Offers application within infectious disease and potential for a number of other indications

## Mechanism



## Results

### Screening Assays



### Confirmatory/Multiplex Assays



## Sexually Transmitted Diseases

### HIV

- 35 million people living with HIV/AIDS worldwide (2013)
- More than 1.1 million people in the U.S. are living with HIV infection, and approximately 1 in 8 are unaware of their infection

### Syphilis

- Approx. 12 million people globally become ill with syphilis annually
- From 2005-2013, syphilis cases in the U.S. nearly doubled, from 8,724 to 16,663

## Fever Diseases

### Malaria

- Approximately 214 million infections and 438,000 deaths annually (2015)

### Dengue Fever

- Approximately 400 million infections annually with 40% of the world population at risk (2015)

### Ebola

- Approximately 28,000 infections and 11,000 deaths in 2014 – 2015

### Zika

- In February 2016, WHO declared the Zika virus a 'public health emergency of international concern,' and the virus has now spread to more than forty countries.

## DPP® PIPELINE & COLLABORATORS

### Chembio Internal Development:

- DPP® HIV-Syphilis Assay (testing in U.S. market)
- DPP® Malaria Assay
- DPP® Chikungunya Assay

### Development Collaborations:

- DPP® Malaria Oral Fluid/Saliva – The Bill & Melinda Gates Foundation
- DPP® Zika – The Paul G. Allen Family Foundation
- DPP® Dengue – Undisclosed collaborator
- DPP® Zika/Dengue/Chikungunya – The Paul G. Allen Family Foundation
- DPP® Fever Panel – The Paul G. Allen Ebola Program
- DPP® Malaria/Ebola & DPP® Ebola Assays – CDC
- DPP® Flu Immunostatus – CDC Contractor
- DPP® Traumatic Brain Injury – Perseus Science Group LLC
- DPP® Cancer (a specific form) – Undisclosed collaborator

### Tech Transfer and Distribution:

- DPP® technology for Geenius™ HIV 1/2 Confirmatory Assay – Bio Rad
- DPP® product distribution in Brazil – Oswaldo Cruz Foundation
- DPP® co-branding and distribution in Brazil – Labtest, Diagnostica SA
- DPP® tech transfer, manufacture and distribution in Malaysia – RVR
- DPP® Micro Reader

## SENIOR EXECUTIVE OFFICERS

**John J. Sperzel III**  
*Chief Executive Officer*

**Richard Larkin, CPA**  
*Chief Financial Officer*

**Sharon Klugewicz, M.S.**  
*Chief Operating Officer*

**Javan Esfandiari, M.S.**  
*Chief Science & Technology Officer*

**Chembio Diagnostics, Inc.**  
3661 Horseblock Road  
Medford, NY 11763  
631-924-1135  
www.chembio.com

**Company Contact**  
Susan Norcott  
Chembio Diagnostics, Inc.  
631-924-1135, ext. 125  
snorcott@chembio.com

**Investor Relations**  
Stephanie Diaz  
Vida Strategic Partners  
415-675-7401  
sdiaz@vidasp.com